Skip to main content

Advertisement

SpringerLink
Log in

CNS Immune Responses Following Experimental Stroke

  • Translational Research
  • Published:
Neurocritical Care Aims and scope Submit manuscript

Abstract

Background and purpose

Animals subjected to an inflammatory insult with lipopolysaccharide (LPS) at the time of stroke are predisposed to develop a detrimental autoimmune response to myelin basic protein (MBP). In this study, we sought to determine whether other inflammatory stimuli could similarly invoke central nervous system (CNS) autoimmunity and whether these detrimental autoimmune responses occurred to antigens other than MBP.

Methods

Male Lewis rats underwent 3 h middle cerebral artery occlusion (MCAO) and received intraperitoneal injections of LPS, staphylococcal enterotoxin B (SEB), lipoteichoic acid (LTA) or saline at the time of reperfusion. Behavioral tests were performed at set time intervals after MCAO and animals were sacrificed at 1 month to analyze the immune response to MBP, neuron specific enolase (NSE) and proteolipid protein (PLP).

Results

Lymphocytes from SEB treated animals were highly reactive to all tested CNS antigens, but treatment with LPS was most likely to lead to a Th1(+) response. A Th1(+) response to MBP, NSE or PLP in spleen was associated with worse outcome, although the response to NSE was most predictive of poor outcome. Animals with a cell mediated autoimmune response to either MBP or NSE in spleen had a concomitant humoral response to these antigens.

Conclusions

These data show that LPS, but not other inflammatory stimuli, increase the likelihood of developing a detrimental autoimmune response to an array of brain antigens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Netea MG, van der Graaf C, Van der Meer JW, Kullberg BJ. Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. J Leukoc Biol. 2004;75:749–55.

    Article  CAS  PubMed  Google Scholar 

  2. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197–216.

    Article  CAS  PubMed  Google Scholar 

  3. Becker KJ, Kindrick DL, Lester MP, Shea C, Ye ZC. Sensitization to brain antigens after stroke is augmented by lipopolysaccharide. J Cereb Blood Flow Metab. 2005;25:1634–44.

    Article  CAS  PubMed  Google Scholar 

  4. Kilic U, Kilic E, Matter CM, Bassetti CL, Hermann DM. TLR-4 deficiency protects against focal cerebral ischemia and axotomy-induced neurodegeneration. Neurobiol Dis. 2008;31:33–40.

    Article  CAS  PubMed  Google Scholar 

  5. Caso JR, Pradillo JM, Hurtado O, Leza JC, Moro MA, Lizasoain I. Toll-like receptor 4 is involved in subacute stress-induced neuroinflammation and in the worsening of experimental stroke. Stroke. 2008;39:1314–20.

    Article  CAS  PubMed  Google Scholar 

  6. Cao CX, Yang QW, Lv FL, Cui J, Fu HB, Wang JZ. Reduced cerebral ischemia-reperfusion injury in Toll-like receptor 4 deficient mice. Biochem Biophys Res Commun. 2007;353:509–14.

    Article  CAS  PubMed  Google Scholar 

  7. Aslanyan S, Weir CJ, Diener HC, Kaste M, Lees KR. Pneumonia and urinary tract infection after acute ischaemic stroke: a tertiary analysis of the GAIN International trial. Eur J Neurol. 2004;11:49–53.

    Article  CAS  PubMed  Google Scholar 

  8. Harms H, Prass K, Meisel C, et al. Preventive antibacterial therapy in acute ischemic stroke: a randomized controlled trial. PLoS ONE. 2008;3:e2158.

    Article  PubMed  Google Scholar 

  9. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20:84–91.

    CAS  PubMed  Google Scholar 

  10. Huang W, Koller LD. Superantigen activation and kinetics of cytokines in the Long-Evans rat. Immunology. 1998;95:331–8.

    Article  CAS  PubMed  Google Scholar 

  11. Chatterjee PK, Zacharowski K, Cuzzocrea S, et al. Lipoteichoic acid from Staphylococcus aureus reduces renal ischemia/reperfusion injury. Kidney Int. 2002;62:1249–63.

    Article  CAS  PubMed  Google Scholar 

  12. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986;17:472–6.

    CAS  PubMed  Google Scholar 

  13. Hernandez TD, Schallert T. Seizures and recovery from experimental brain damage. Exp Neurol. 1988;102:318–24.

    Article  CAS  PubMed  Google Scholar 

  14. Becker K, Kindrick D, McCarron R, Hallenbeck J, Winn R. Adoptive transfer of myelin basic protein-tolerized splenocytes to naive animals reduces infarct size: a role for lymphocytes in ischemic brain injury? Stroke. 2003;34:1809–15.

    Article  CAS  PubMed  Google Scholar 

  15. Becker KJ. Sensitization and tolerization to brain antigens in stroke. Neuroscience. 2009;158:1090–7.

    Article  CAS  PubMed  Google Scholar 

  16. Pasare C, Medzhitov R. Toll-like receptors and acquired immunity. Semin Immunol. 2004;16:23–6.

    Article  CAS  PubMed  Google Scholar 

  17. Toubi E, Shoenfeld Y. Toll-like receptors and their role in the development of autoimmune diseases. Autoimmunity. 2004;37:183–8.

    Article  CAS  PubMed  Google Scholar 

  18. Huang YH, Haegerstrand A, Frostegard J. Effects of in vitro hyperthermia on proliferative responses and lymphocyte activity. Clin Exp Immunol. 1996;103:61–6.

    Article  CAS  PubMed  Google Scholar 

  19. Croft M, Dubey C. Accessory molecule and costimulation requirements for CD4 T cell response. Crit Rev Immunol. 1997;17:89–118.

    CAS  PubMed  Google Scholar 

  20. Hickey WF, Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science. 1988;239:290–2.

    Article  CAS  PubMed  Google Scholar 

  21. Kato H, Kogure K, Liu XH, Araki T, Itoyama Y. Progressive expression of immunomolecules on activated microglia and invading leukocytes following focal cerebral ischemia in the rat. Brain Res. 1996;734:203–12.

    Article  CAS  PubMed  Google Scholar 

  22. Hathcock KS, Laszlo G, Pucillo C, Linsley P, Hodes RJ. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med. 1994;180:631–40.

    Article  CAS  PubMed  Google Scholar 

  23. Jiang-Shieh YF, Yeh KY, Wei IH, et al. Responses of microglia in vitro to the gram-positive bacterial component, lipoteichoic acid. J Neurosci Res. 2005;82:515–24.

    Article  CAS  PubMed  Google Scholar 

  24. Lee SJ, Lee S. Toll-like receptors and inflammation in the CNS. Curr Drug Targets Inflamm Allergy. 2002;1:181–91.

    Article  CAS  PubMed  Google Scholar 

  25. Zanin-Zhorov A, Tal-Lapidot G, Cahalon L, et al. Cutting edge: T cells respond to lipopolysaccharide innately via TLR4 signaling. J Immunol. 2007;179:41–4.

    CAS  PubMed  Google Scholar 

  26. Manicassamy S, Ravindran R, Deng J, et al. Toll-like receptor 2-dependent induction of vitamin A-metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity. Nat Med. 2009;15:401–9.

    Article  CAS  PubMed  Google Scholar 

  27. Kerfoot SM, Long EM, Hickey MJ, et al. TLR4 contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease. J Immunol. 2004;173:7070–7.

    CAS  PubMed  Google Scholar 

  28. Kato N, Fujii Y, Agata N, et al. Experimental murine model for autoimmune myocarditis using Klebsiella pneumoniae O3 lipopolysaccharide as a potent immunological adjuvant. Autoimmunity. 1993;14:231–6.

    Article  CAS  PubMed  Google Scholar 

  29. Zaccone P, Fehervari Z, Blanchard L, Nicoletti F, Edwards CK 3rd, Cooke A. Autoimmune thyroid disease induced by thyroglobulin and lipopolysaccharide is inhibited by soluble TNF receptor type I. Eur J Immunol. 2002;32:1021–8.

    Article  CAS  PubMed  Google Scholar 

  30. Proft T, Fraser JD. Bacterial superantigens. Clin Exp Immunol. 2003;133:299–306.

    Article  CAS  PubMed  Google Scholar 

  31. Friedman SM, Tumang JR, Crow MK. Microbial superantigens as etiopathogenic agents in autoimmunity. Rheum Dis Clin North Am. 1993;19:207–22.

    CAS  PubMed  Google Scholar 

  32. Ivars F. Superantigen-induced regulatory T cells in vivo. Chem Immunol Allergy. 2007;93:137–60.

    Article  CAS  PubMed  Google Scholar 

  33. Romagnani S. Regulation of the T cell response. Clin Exp Allergy. 2006;36:1357–66.

    Article  CAS  PubMed  Google Scholar 

  34. Gee JM, Kalil A, Thullbery M, Becker KJ. Induction of immunologic tolerance to myelin basic protein prevents central nervous system autoimmunity and improves outcome after stroke. Stroke. 2008;39:1575–82.

    Article  PubMed  Google Scholar 

  35. Hofstetter HH, Targoni OS, Karulin AY, Forsthuber TG, Tary-Lehmann M, Lehmann PV. Does the frequency and avidity spectrum of the neuroantigen-specific T cells in the blood mirror the autoimmune process in the central nervous system of mice undergoing experimental allergic encephalomyelitis? J Immunol. 2005;174:4598–605.

    CAS  PubMed  Google Scholar 

  36. Muhallab S, Lidman O, Weissert R, Olsson T, Svenningsson A. Intra-CNS activation by antigen-specific T lymphocytes in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2001;113:202–11.

    Article  CAS  PubMed  Google Scholar 

  37. Wang WZ, Olsson T, Kostulas V, Hojeberg B, Ekre HP, Link H. Myelin antigen reactive T cells in cerebrovascular diseases. Clin Exp Immunol. 1992;88:157–62.

    Article  CAS  PubMed  Google Scholar 

  38. Bornstein NM, Aronovich B, Korczyn AD, Shavit S, Michaelson DM, Chapman J. Antibodies to brain antigens following stroke. Neurology. 2001;56:529–30.

    CAS  PubMed  Google Scholar 

  39. Dambinova SA, Khounteev GA, Izykenova GA, Zavolokov IG, Ilyukhina AY, Skoromets AA. Blood test detecting autoantibodies to N-methyl-d-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem. 2003;49:1752–62.

    Article  CAS  PubMed  Google Scholar 

  40. Dale RC, Candler PM, Church AJ, Wait R, Pocock JM, Giovannoni G. Neuronal surface glycolytic enzymes are autoantigen targets in post-streptococcal autoimmune CNS disease. J Neuroimmunol. 2006;172:187–97.

    Article  CAS  PubMed  Google Scholar 

  41. Fillit HM, Kemeny E, Luine V, Weksler ME, Zabriskie JB. Antivascular antibodies in the sera of patients with senile dementia of the Alzheimer’s type. J Gerontol. 1987;42:180–4.

    CAS  PubMed  Google Scholar 

  42. Jankovic BD, Horvat J, Djordjijevic D, Ramah A, Fridman V, Spahic O. Brain-associated autoimmune features in heroin addicts: correlation to HIV infection and dementia. Int J Neurosci. 1991;58:113–26.

    Article  CAS  PubMed  Google Scholar 

  43. Braus BK, Hauck SM, Amann B, et al. Neuron-specific enolase antibodies in patients with sudden acquired retinal degeneration syndrome. Vet Immunol Immunopathol. 2008;124:177–83.

    Article  CAS  PubMed  Google Scholar 

  44. Ikeda Y, Maruyama I, Nakazawa M, Ohguro H. Clinical significance of serum antibody against neuron-specific enolase in glaucoma patients. Jpn J Ophthalmol. 2002;46:13–7.

    Article  CAS  PubMed  Google Scholar 

  45. Jankovic BD, Djordjijevic D. Differential appearance of autoantibodies to human brain S100 protein, neuron specific enolase and myelin basic protein in psychiatric patients. Int J Neurosci. 1991;60:119–27.

    Article  CAS  PubMed  Google Scholar 

  46. Dantzer R. Cytokine, sickness behavior, and depression. Immunol Allergy Clin North Am. 2009;29:247–64.

    Article  PubMed  Google Scholar 

  47. Imai T, Hieshima K, Haskell C, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 1997;91:521–30.

    Article  CAS  PubMed  Google Scholar 

  48. Umehara H, Bloom E, Okazaki T, Domae N, Imai T. Fractalkine and vascular injury. Trends Immunol. 2001;22:602–7.

    Article  CAS  PubMed  Google Scholar 

  49. Chapman GA, Moores K, Harrison D, Campbell CA, Stewart BR, Strijbos PJ. Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. J Neurosci. 2000;20:RC87.

    CAS  PubMed  Google Scholar 

  50. Tarozzo G, Campanella M, Ghiani M, Bulfone A, Beltramo M. Expression of fractalkine and its receptor, CX3CR1, in response to ischaemia-reperfusion brain injury in the rat. Eur J Neurosci. 2002;15:1663–8.

    Article  PubMed  Google Scholar 

  51. Soriano SG, Amaravadi LS, Wang YF, et al. Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J Neuroimmunol. 2002;125:59–65.

    Article  CAS  PubMed  Google Scholar 

  52. Denes A, Ferenczi S, Halasz J, Kornyei Z, Kovacs KJ. Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. J Cereb Blood Flow Metab. 2008;28:1707–21.

    Article  CAS  PubMed  Google Scholar 

  53. Kastenbauer S, Koedel U, Wick M, Kieseier BC, Hartung HP, Pfister HW. CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system. J Neuroimmunol. 2003;137:210–7.

    Article  CAS  PubMed  Google Scholar 

  54. Matsunawa M, Isozaki T, Odai T, et al. Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis. Arthritis Rheum. 2006;54:3408–16.

    Article  CAS  PubMed  Google Scholar 

  55. Yajima N, Kasama T, Isozaki T, et al. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations. Arthritis Rheum. 2005;52:1670–5.

    Article  CAS  PubMed  Google Scholar 

  56. Fraticelli P, Sironi M, Bianchi G, et al. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest. 2001;107:1173–81.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

This work was supported by grants from the National Institutes of Neurological Disorders and Stroke (NINDS) (1RO1NS056457).

Author information

Authors and Affiliations

  1. Department of Neurology, University of Washington School of Medicine, Harborview Medical Center, Box 359775 HMC, 325 9th Ave, Seattle, WA, 98104-2499, USA

    Dannielle Zierath, Matthew Thullbery, Jessica Hadwin, J. Michael Gee, Anna Savos, Angela Kalil & Kyra J. Becker

Authors
  1. Dannielle Zierath
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew Thullbery
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jessica Hadwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Michael Gee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anna Savos
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Angela Kalil
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kyra J. Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kyra J. Becker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zierath, D., Thullbery, M., Hadwin, J. et al. CNS Immune Responses Following Experimental Stroke. Neurocrit Care 12, 274–284 (2010). https://doi.org/10.1007/s12028-009-9270-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12028-009-9270-4

Keywords

Search

Navigation